Efficacy of melatonin supplementation in the treatment of periodontitis: a systematic review and meta-analysis

Yuexiang Zhen  
Chongqing Medical University Stomatology College: Stomatological Hospital of Chongqing Medical University  
https://orcid.org/0000-0002-2105-3158

Hui Yue  
Chongqing Medical University

Yiting Xiao  
Chongqing Medical University

Qin Liu  
Chongqing University of Medical Science: Chongqing Medical University

Meilin Zhao (✉ zhaomeilin@hospital.cqmu.edu.cn)  
Chongqing Medical University Stomatology College: Stomatological Hospital of Chongqing Medical University

Research

Keywords: Periodontitis, Melatonin, Nonsurgical periodontal therapy, Meta-analysis

Posted Date: April 1st, 2021

DOI: https://doi.org/10.21203/rs.3.rs-376485/v1

License: © (✉) This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** The aim of this systematic review and meta-analysis was to analyze the additive effects of the melatonin supplementation with nonsurgical periodontal therapy (NSPT) on periodontal status in patients affected by chronic periodontitis.

**Methods:** In December 2020, we searched PubMed, EMBASE, Web of Science, CENTRAL databases and Google Scholar databases. Four RCTs were recruited with the same inclusion criteria. PD and CAL were the primary outcome measures. Subgroup analyses were performed according to health statuses and follow-up times, and Cochran's Q and I-square ($I^2$) tests were used to assess heterogeneity.

**Results:** This review included four RCTs. Four studies reported probing depth (PD) and 3 studies reported clinical attachment loss (CAL). Compared with the placebo groups, the melatonin groups showed a significant reduction in PD (weighted mean difference [WMD], -1.01; 95% confidence intervals [CI], -1.67 to -0.35; $I^2 = 76\%$) and CAL (WMD, -1.08; 95% CI: -1.36 to -0.79, $I^2 = 0\%$). Subgroup analyses revealed that the use of systemic melatonin + NSPT significantly reduced PD and CAL at the 2-, 3-, and 6-month follow-ups compared to NSPT alone, and stronger treatment effects of reducing PD were observed at shorter follow-ups than at longer follow-ups when adjunctive systemic melatonin was used.

**Conclusions:**

Melatonin supplementation in adjunct with nonsurgical periodontal therapy can moderately improve the efficacy of NSPT in reducing PD and greater CAL gain in patients with periodontitis. With the limited evidence available, it is evident that additional good quality RCTs are required to demonstrate additional beneficial effects of oral melatonin supplementation on periodontal clinical parameters after NSPT.

**Background**

Chronic periodontitis (CP) is an inflammatory disease mainly caused by subgingival microbial plaque and characterized by the destruction of tooth-supporting tissues [1, 2]. The damage to periodontal tissue is related to the production of certain harmful substances, including pro-inflammatory cytokines, free radicals, reactive oxygen species and reactive nitrogen, some of which are directly produced by periodontal bacteria and others of which are produced by the host immune response to dysbiotic microbial presence [3, 4]. The release of these products is largely sustained, driving the progressive loss of connective tissue attachment and alveolar bone and even tooth loss if not treated promptly [3, 5]. Nonsurgical periodontal therapy (NSPT), a standard treatment for periodontitis, mainly includes professional oral hygiene instructions (OHI) and full-mouth subgingival scaling and root planing (SRP), which mechanically removes dental plaque and calculus on the root surface. However, the limitations of inaccessible periodontal defects [6] and poor host inflammatory-immune response [7] can influence the effectiveness of periodontal healing. Although NSPT can successfully suppress the progression of inflammation and prevent progressive bone loss in some cases, the ability of the periodontium to their return to original form and function is still limited. Regarding these issues, periodontal clinicians have considered the use of host modulatory agents as adjuvant therapies to modulate the host immune response and boost the regeneration of periodontal tissue [8, 9]. Host modulatory agents can affect the host immune response through different pharmacological mechanisms [4, 9]. For example, tetracycline antibiotics inhibit the synthesis of matrix metalloproteinase [10], nonsteroidal anti-inflammatory drugs inhibit the release of pro-inflammatory cytokines and prostaglandins [11], and bone-sparing agents block the expression of osteoclasts [12, 13]. However, these drugs may cause resistance, opportunistic infections, and other side effects [14, 15].

Melatonin (N-acetyl-5-methoxy-tryptamine) is an important hormone that is mainly secreted by the pineal gland and is associated with the circadian rhythm [16, 17]. Melatonin can be correlated with the development and severity of periodontitis [18]. Previous studies have shown that the level of melatonin in plasma and saliva is significantly decreased in patients with periodontitis compared to healthy patients [19, 20]. Melatonin can be used as a dietary supplement or as a prescription drug in different countries [4]. Melatonin possesses a wide spectrum of essential properties, such as anti-inflammatory,
immunomodulatory [21, 22] and antioxidant effects [22, 23], free radical scavenging; bone metabolism regulation [24]. As such, melatonin could be used as a novel host modulatory agent to modulate the host response in patients with destructive periodontitis [25]. Therefore, research on melatonin supplementation after NSPT in the treatment of periodontal disease has attracted the attention of clinicians.

Currently, some publications have reported that systemic melatonin after NSPT in patients with periodontitis has advantages in reducing probing depth (PD) and clinical attachment loss (CAL) compared with NSPT alone [26, 27]. However, other studies have noted no significant difference in the results of the clinical outcomes for NSPT combined with melatonin supplementation compared with NSPT alone [28]. This uncertain evidence is not conducive to the clinical application or promotion of melatonin in patients with periodontitis.

To the best of our knowledge, there is no systematic review or meta-analysis of RCTs evaluating the effects of NSPT combined with melatonin on clinical outcomes in patients with periodontitis. Therefore, the primary purpose of this study was to summarize the available evidence and determine the effects of melatonin supplementation in combination with NSPT on clinical outcomes in patients with periodontitis.

Methods

Guidelines

We conducted this study following the guidelines of the Transparent Reporting of Systematic Reviews and Meta-Analyses (PRISMA) statement [29].

Search plan

We comprehensively searched the PubMed, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases for relevant articles published before April 2020 in the English language. We used the following terms (MeSH) and free text keywords: population ["periodontal disease" OR "chronic periodontitis"], intervention ["periodontal therapy" OR "periodontal debridement" OR "nonsurgical periodontal debridement" AND "melatonin"]. We also manually checked the reference lists of selected studies to identify any possible eligible citations. The detailed search strategy is illustrated in supplementary Table S1.

Two investigators (YX.Z and H.Y.) independently conducted the study screening process. We deleted duplicate publications and excluded those that were ineligible by reviewing titles and abstracts. Finally, we read the full text carefully to identify eligible studies. Any disagreement during the study selection process was settled by discussion. To identify additional publications, we manually searched the reference lists of the included studies. We did not contact the original authors for further information.

Inclusion and exclusion criteria

We included RCTs with no minimum duration that evaluated the effects of systemic melatonin adjunctive to NSPT compared with NSPT plus a placebo or alone in patients with periodontitis. The primary outcome measures were PD and CAL. The secondary outcome measure was the occurrence of adverse effects related to melatonin administration. We excluded case reports, animal studies, and studies that used local melatonin delivery adjunctive to NSPT. In addition, we also excluded studies that used systemic melatonin with other concomitant oral medications.

Data extraction

Two investigators (ML.Z. and YX.Z.) independently collected and extracted the following data: first author’s name, publication date, study location, study design, participants’ characteristics, total sample size and dropouts, intervention (the treatment conditions of NSPT; dose, usage of melatonin, and duration of treatment), type of systematic disease, periodontitis definition, study duration, outcome measures, and sponsor. Disagreements regarding extracted information between the two reviewers were settled by discussion.

Quality assessment
Two investigators (Q.L. and YT.X.) individually performed the quality assessment of included trials based on the Cochrane Collaboration’s tool [30]. The third reviewer resolved any disagreements regarding the study quality assessment. The methodological quality included the following criteria: randomization generation, and allocation concealment; blinding of participants, personnel and examiners; outcome assessment; incomplete outcome data; selective outcome reporting; and other sources of bias. Overall, the risk of study bias was categorized as follows: 1) low risk of bias: there was a “low” risk answer for all domains; 2) moderate risk of bias: there was an “unclear” risk answer for one or more domains; 3) high risk of bias: there was a “high” risk answer for one or more domains.

Statistical analysis
Two investigators (Q.L. and H.Y.) determined the effects of NSPT plus melatonin supplementation and NSPT alone on periodontal parameter variables in patients with CP. Trial outcome data were pooled into weighted mean differences (WMDs) with 95% confidence intervals (CIs) using RevMan 5.3 software (Cochrane Collaboration). Heterogeneity among studies was estimated using the Cochran (Q) and I-square tests ($I^2$). $P<0.1$ and $I^2 > 50\%$ indicated substantial heterogeneity. Otherwise, when $P \geq 0.1$ and $I^2 \leq 50\%$, heterogeneity was acceptable [30]. We used a random-effects model for our meta-analysis. Owing to the small number of included studies, the assessment of publication bias by using a funnel plot was not evaluated [30].

Results

Literature search
A total of 151 potentially eligible publications were identified from the electronic databases search. Ninety-eight studies were screened after duplicate removal. The full texts of 10 studies were retrieved according to the established inclusion criteria. Ultimately, four studies [25–28] were finally considered eligible for inclusion in this review (Fig. 1).

Characteristics of the included studies
The detailed information of the included studies for the intervention and placebo groups is summarized in Table 1, Table 2 and Table S2. Overall, four included RCTs [25–28] reported 198 patients who presented mild to severe CP. The investigators of four studies identified CP as involving at least one site with a PD of 4 millimetres or greater. The investigators of three studies provided the CAL threshold value in the definition of CP [28], while one study did not report CAL values or bone loss [28]. The investigators of two studies [25, 28] recruited systematically healthy patients with CP. The remaining two studies recruited patients with comorbidities, one study recruited patients with primary insomnia [27], and the other study recruited patients with type 2 diabetes mellitus (DM) [26]. The dose of melatonin varied from 1 to 10 mg/day. The participants of two included studies received systemic melatonin for two months [26–28], while the participants of the other two studies received systemic melatonin for one month [25]. Tinto and colleagues [25] reported that SRP was performed in one-session in the full mouth under local anaesthesia and it took nearly 45 minutes per quadrant. El-Sharkawy and colleagues [27] only reported SRP over two separate visits, but the investigators of three studies did not define SRP in detail [26–28]. The participants of 2 included studies did not receive local antimicrobials after SRP [26, 28], but El-Sharkawy [27] and Tinto [25] combined antimicrobial treatment with a 0.12% and 0.20% chlorhexidine rinse twice a day for two weeks for study participants after SRP, respectively.
Table 1  
Characteristics of the included studies

<table>
<thead>
<tr>
<th>Author year, country</th>
<th>Country</th>
<th>Study design</th>
<th>Sample size (no. dropouts)</th>
<th>Mean age or range (y)</th>
<th>Smokers</th>
<th>Other systemic condition</th>
<th>Periodontitis definition (mm)/clinical examination</th>
<th>Duration (mo)</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chitsazi et al. 2017 [28], Iran</td>
<td>Iran</td>
<td>RCT parallel design</td>
<td>60 (0)</td>
<td>23–65</td>
<td>No</td>
<td>No</td>
<td>Moderate to severe CP, PD ≥ 5 UNC-15 probe</td>
<td>3, 6</td>
<td>Tabriz University Dental and Periodontal Research Center</td>
</tr>
<tr>
<td>El-Sharkawy et al. 2019 [27], Egypt</td>
<td>Egypt</td>
<td>RCT parallel design</td>
<td>80 (6)</td>
<td>38–55</td>
<td>No</td>
<td>primary insomnia</td>
<td>≥ 20 teeth, moderate to severe CP, PD ≥ 5 and radiographic CAL ≥ 4 at least three sites in each quadrant Probe not reported</td>
<td>3, 6</td>
<td>No</td>
</tr>
<tr>
<td>Bazyar et al. 2018 [26], Iran</td>
<td>Iran</td>
<td>RCT parallel design</td>
<td>50 (6)</td>
<td>T: 53.72 ± 6.68 C: 51.45 ± 5.03</td>
<td>No</td>
<td>type 2 Diabetes mellitus</td>
<td>Mild and moderate CP, PD ≥ 4 and CAL = 1–4 UNC-15 probe</td>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>Tinto et al. 2019 [25], Italy</td>
<td>Italy</td>
<td>RCT parallel design</td>
<td>20 (0)</td>
<td>30–70</td>
<td>No</td>
<td>No</td>
<td>Severe CP, CAL ≥ 5, ≥ 20 teeth, PD ≥ 6 Probe not reported</td>
<td>6</td>
<td>Periodontal Unit of Santa Apollonia Dental Center</td>
</tr>
</tbody>
</table>

*RCT Randomized controlled trial, T Test group, C Control group, PD probing depth, CAL clinical attachment loss, mm millimetre, mo months, CP chronic periodontitis*
Table 2
Participants, interventions, outcomes and results

<table>
<thead>
<tr>
<th>Author, year, country</th>
<th>Participants</th>
<th>Groups</th>
<th>Interventions</th>
<th>Drug usage and dosage</th>
<th>Outcome variables/adverse effects</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chitsazi et al. 2017 [28], Iran</td>
<td>T: N = 40 C: N = 40 31 females, 29 males</td>
<td>T: NSPT + melatonin  C: NSPT</td>
<td>OHI + SRP</td>
<td>2 mg melatonin a day for 1 mo</td>
<td>PD, CAL</td>
<td>None</td>
</tr>
<tr>
<td>El-Sharkawy et al. 2019 [27], Egypt</td>
<td>T: N = 38 C: N = 36 33 females, 41 males</td>
<td>T: NSPT + melatonin capsule  C: NSPT + placebo</td>
<td>OHI + two-session SRP + 0.12% chlorhexidine rinse for 2 weeks</td>
<td>10 mg melatonin once per day 1 hour before bedtime for 2 mo</td>
<td>CAL, PD</td>
<td>Cases of headache, dizziness, nausea, constipation, diarrhea, and abdominal cramp ≤ 2</td>
</tr>
<tr>
<td>Bazyar et al. 2018 [26], Iran</td>
<td>T: N = 22 C: N = 22 30 females, 14 males</td>
<td>T: NSPT + melatonin tablets  C: NSPT + placebo</td>
<td>OHI + SRP</td>
<td>3 mg melatonin once a day 1 hour before bedtime for 2 mo</td>
<td>PD, CAL</td>
<td>None</td>
</tr>
<tr>
<td>Tinto et al. 2019 [25], Italy</td>
<td>T: N = 10 C: N = 10 8 females, 12 males</td>
<td>T: NSPT + melatonin tablets  C: NSPT + placebo</td>
<td>OHI + one-session SRP (1 quadrant per 45 minutes with local anesthesia) + 0.20% chlorhexidine rinse for 2 weeks</td>
<td>1 mg melatonin once a day at bedtime for 1 mo</td>
<td>PD</td>
<td>T: 20% sleepiness and 10% headache</td>
</tr>
</tbody>
</table>

T test group, C control group, NSPT non-surgical periodontal therapy, PD probing depth, CAL clinical attachment loss, mo months, OHI oral hygiene instructions, SRP scaling and root planing

Quality assessment of selected studies

Of the four included RCTs, three had a low risk of bias [25–27], and one exhibited a moderate risk of bias [28]. The risk of bias quality assessments of the included RCTs is presented in Table 3. All included studies received a “yes” answer for aspects of randomized sequence generation, allocation concealment, blinding of participants and personnel, complete data, and other bias. The risk answer was assigned because the blinding of allocation for the participants was not described. Overall, the quality of studies was considered moderate in 1 RCT and high in 3 RCTs.
The primary outcomes
The investigators of the four included studies reported PD [25–28] between baseline and follow-up visits, and the investigators of three studies reported CAL [26–28]. Overall, there were significant differences in reducing PD (WMD, -1.01; 95% CI, -1.67 to -0.35; $I^2 = 76\%$) and CAL (WMD, -1.08; 95% CI: -1.36 to -0.79, $I^2 = 0\%$), as presented in Fig. 2 and Fig. 3. There was substantial heterogeneity in PD ($I^2 = 76\%$) among the studies.

Secondary outcome measures
One study [25] mentioned that, in the melatonin group, two patients reported sleepiness, and one patient reported headache. One trial [27] reported cases of headache, dizziness, nausea, and gastrointestinal reaction that were less than or equal to two in number. The other two trials did not report adverse effects [26, 28].

Subgroup analyses
The findings of the subgroup analysis by health status demonstrated that the systemic melatonin adjunctive to NSPT group showed a significant difference in PD compared with the NSPT alone group with respect to patients with comorbidities (WMD, -1.01; 95% CI, -1.61 to -0.35; $I^2 = 72\%$) and systemically healthy patients (WMD, -0.77; 95% CI, -1.91 to -0.36; $I^2 = 88\%$) (Fig. 5). However, high degrees of heterogeneity were observed between studies.

We also performed a subgroup analysis by follow-up period for CAL and found that melatonin supplementation after NSPT resulted in significantly less CAL at the 2- (WMD, -1.18; 95% CI, -1.56 to -0.80), 3- (WMD, -0.83; 95% CI, -1.23 to -0.43), and 6-month (WMD, -0.94; 95% CI, -1.38 to -0.51) visits than NSPT alone (Fig. 6). The subgroup analysis for CAL showed a low heterogeneity.

Discussion
Due to its antioxidant and anti-inflammatory properties, and modulatory effects on bone formation, periodontal practitioners have begun to consider the use of melatonin supplementation as an adjunctive therapeutic option with NSPT in the treatment of periodontitis [4]. However, some previous publications have reported that the effects of systemic melatonin on clinical periodontal parameters are controversial in patients with periodontitis [25–28]. This meta-analysis demonstrated that the use
of systemic melatonin + NSPT showed modest additional benefits in reducing PD by 1.12 mm and in decreasing CAL by 1.02 mm compared to NSPT + a placebo or alone. The findings of the subgroup analysis also suggested stronger treatment effects of PD reduction in shorter follow-up periods than in longer follow-up periods when adjunctive systemic melatonin was used. It is worth noting that melatonin has a wide safety margin, but systemic melatonin may have some side effects, such as sleepiness and headache [25, 27]. Thus, when using systemic melatonin, periodontal clinicians should consider its potentially undesired side effects.

PD reduction and CAL gain are often considered clinical indicators of the successful treatment of periodontitis [31]. This systematic review and meta-analysis demonstrated that, compared with NSPT alone, the use of systemic melatonin + NSPT significantly reduced PD and CAL. Over the years, studies have demonstrated that the biological mechanisms of melatonin on the ability of periodontal healing could be attributed to the following. First, the intrinsic anti-inflammatory and antioxidant properties of melatonin can promote the early healing of periodontal tissue [32]. Studies have shown that melatonin can reduce highly destructive free radicals and oxygen and nitrogen reactive substances that cause oxidative damage to periodontal tissues, increase the antioxidant capacity of the host and depress pro-inflammatory cytokine production [21, 33], thus reducing the adverse effects of the host’s immune system on periodontal tissues. On the other hand, melatonin plays an important role in regulating bone tissue formation and bone loss. Melatonin can effectively suppress the receptor activator of the nuclear factor-kappa B ligand/osteoprotegerin (RANKL/OPG) signalling pathway, which is activated by osteoclast receptors, potentially suppressing the progression of alveolar bone loss [34]. Melatonin can promote osteoblastic differentiation and stimulate the synthesis of new bone matrix [24], which is manifested in the improvement of new attachment generation. Additionally, melatonin exerts a direct antimicrobial effect on some periodontal cariogenic bacteria, potentially reducing the inflammatory response of periodontal tissue [35]. These mechanisms provide possible evidence for the potential therapeutic effect of melatonin on the healing of periodontal soft and hard tissues in patients with periodontitis.

In the present study, the overall meta-analysis showed considerable heterogeneity across studies (PD, $I^2 = 76.0\%$). The observed heterogeneity may also be attributed to differences in the participants’ characteristics, health statuses, severity and range of periodontal disease, the dose and duration of melatonin, treatment conditions of NSPT, and follow-up periods among studies. First, we performed subgroup analyses of PD according to different follow-up times and health statuses. The health status subgroup analysis showed that patients with comorbidities and systemically healthy patients showed significant heterogeneity, and the follow-up time subgroup analysis suggested low heterogeneity at three months and moderate heterogeneity at six months. The follow-up time subgroup analysis showed that the heterogeneity in our study was acceptable according to the follow-up time. Therefore, the reason for the high heterogeneity may be that the follow-up time might account for more heterogeneity than the health status. Second, as for treatment conditions, Tinto and colleagues [25] carried out SRP in one-session in the full mouth under local anaesthesia and it took nearly 45 minutes per quadrant, while the investigators of three studies [26–28] did not mention the detailed treatment modality of SRP. In addition, El-Sharkawy [27] and Tinto [25] used a 0.12% and 0.20% chlorhexidine rinse in both melatonin and placebo groups after SRP, respectively, but the remaining two studies [26, 28] did not take any local antimicrobials after surgery. We also noted that the dose of melatonin ranged from 1 to 10 mg/day and the duration of melatonin supplementation of included studies varied from 4 weeks to 2 months. However, due to the paucity of studies, which provided limited information, we could not perform subgroup analyses of other potentially confounding factors. Further scientific RCTs are needed to provide additional information regarding the use of melatonin in the treatment of periodontitis.

This investigation is the first systematic review and meta-analysis to determine the effects of systemic melatonin + NSPT compared to NSPT alone on clinical outcomes in patients with periodontitis. All the included studies were randomized, parallel-designed trials, and all of them were published in the last three years. We considered three included studies to have a low risk of bias and one study to have a moderate risk of bias. For analysis purposes, we performed subgroup analyses according to follow-up periods and health status. However, some of the limitations of our research should be recognized. Melatonin is a novel host modulatory agent for use in periodontal diseases, so the number of clinical studies is relatively small. We included only four RCTs and consequently we could not assess the publications by funnel plots.
Conclusion

The present meta-analysis shows that systemic melatonin as an adjunct to NSPT can moderately reduce PD and improve CAL in patients with CP. The use of systemic melatonin may improve the efficacy of NSPT for the treatment of CP and thereby promote improved capacity for periodontal healing. Considering the limitations of our study, it is recommended to conduct good quality RCTs with a large sample size to assess the safety and efficacy of oral melatonin. Based on data of future clinical trials, systemic melatonin might be used as a reliable adjunctive therapy for chronic periodontitis in patients.

Abbreviations

NSPT: Nonsurgical periodontal therapy; PD: Probing depth; CAL: Clinical attachment loss; WMD: Weighted mean difference; CI: Confidence interval; RCTs: Randomized clinical trials; I²: I-square; CP: Chronic periodontitis; OHI: Oral hygiene instructions; SRP: Scaling and root planning; PRISMA: Transparent Reporting of Systematic Reviews and Meta-analyses; CENTRAL: The Cochrane Central Register of Controlled Trials; WMDs: Weighted mean differences; DM: Diabetes mellitus; RANKL/OPG: Receptor activator of the nuclear factor-kappa B ligand/osteoprotegerin.

Declarations

Ethics approval and consent to participate

Not applicable.

Availability of data and materials

The data supporting the findings are available in the databases PubMed, EMBASE and CENTRAL.

Consent to publish

Not applicable.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

Not applicable.

Funding

This study was supported by the Program for Innovation Team Building at Institutions of Higher Education in Chongqing in 2016 (CXTDG201602006) and Chongqing medical research project (2015msxm055).

Authors’ contributions

Yuexiang Zhen and Hui Yue searched the literature and selected the studies. Meilin Zhao and Yuexiang Zhen extracted the data. Qin Liu and Yiting Xiao assessed the quality of the included studies. Qin Liu and Hui Yue analysed the data. Yuexiang Zhen, Meilin Zhao, Hui Yue, Qin Liu and Yiting Xiao drafted the article. Yuexiang Zhen and Meilin Zhao designed the study, interpreted the data, and revised the article. All authors approved the submission.

References

1. Holtfreter B, Albandar JM, Dietrich T, Dye BA, Eaton KA, Eke PI, Papapanou PN, Kocher T: Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: Proposed standards from the Joint EU/USA Periodontal


Figures
Figure 1

Flow diagram of the study selection process.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental</th>
<th>Control</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td>Mean</td>
</tr>
<tr>
<td>Bazari et al., 2018</td>
<td>2.59</td>
<td>1.04</td>
<td>22</td>
<td>4.36</td>
</tr>
<tr>
<td>Chitsazi et al., 2017</td>
<td>3.54</td>
<td>1.45</td>
<td>20</td>
<td>4.92</td>
</tr>
<tr>
<td>El-Sharkawy et al., 2019</td>
<td>2.3</td>
<td>0.9</td>
<td>38</td>
<td>3</td>
</tr>
<tr>
<td>Tinto et al., 2019</td>
<td>2.45</td>
<td>0.91</td>
<td>10</td>
<td>2.67</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>90</td>
<td>88</td>
<td>100.0%</td>
<td>-1.01 [-1.67, -0.35]</td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.33; Chi² = 12.69, df = 3 (P = 0.005); I² = 76%

Test for overall effect: Z = 3.00 (P = 0.003)

Figure 2
Forest plot presenting overall WMDs of post-therapy on probing depth by comparing melatonin + NSPT vs. NSPT.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental Mean</th>
<th>Experimental SD</th>
<th>Control Mean</th>
<th>Control SD</th>
<th>Total</th>
<th>Weight</th>
<th>Mean Difference IV, Random, 95% CI</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bazyar et al., 2018</td>
<td>1.59</td>
<td>0.59</td>
<td>22</td>
<td>2.77</td>
<td>0.68</td>
<td>22</td>
<td>56.9% -1.18 [-1.56, -0.80]</td>
<td></td>
</tr>
<tr>
<td>Chitsazi et al., 2017</td>
<td>3.22</td>
<td>1.52</td>
<td>20</td>
<td>4.56</td>
<td>1.16</td>
<td>20</td>
<td>11.5% -1.34 [-2.18, -0.50]</td>
<td></td>
</tr>
<tr>
<td>El-Sharkawy et al., 2019</td>
<td>2.6</td>
<td>1</td>
<td>38</td>
<td>3.4</td>
<td>1.2</td>
<td>36</td>
<td>31.6% -0.80 [-1.30, -0.30]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>80</td>
<td>78</td>
<td>100.0%</td>
<td></td>
<td></td>
<td></td>
<td>-1.08 [-1.36, -0.79]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.00; Chi² = 1.82, df = 2 (P = 0.40); I² = 0%
Test for overall effect: Z = 7.45 (P < 0.00001)

Figure 3

Forest plot presenting overall WMDs of post-therapy on clinical attachment loss by comparing melatonin + NSPT vs. NSPT.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Melatonin+NSPT groups Mean</th>
<th>Melatonin+NSPT groups SD</th>
<th>Only NSPT groups Mean</th>
<th>Only NSPT groups SD</th>
<th>Total</th>
<th>Weight</th>
<th>Mean Difference IV, Random, 95% CI</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2.1 2 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bazyar et al., 2018</td>
<td>2.59</td>
<td>1.04</td>
<td>22</td>
<td>4.36</td>
<td>1.04</td>
<td>22</td>
<td>100.0% -1.77 [-2.38, -1.16]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22</td>
<td>22</td>
<td>-1.77 [-2.38, -1.16]</td>
<td>-1.77 [-2.38, -1.16]</td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 5.64 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2.2 3 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chitsazi et al., 2017</td>
<td>4.56</td>
<td>1.31</td>
<td>20</td>
<td>5.23</td>
<td>1.89</td>
<td>20</td>
<td>15.6% -0.67 [-1.68, 0.34]</td>
<td></td>
</tr>
<tr>
<td>El-Sharkawy et al., 2019</td>
<td>2.4</td>
<td>1</td>
<td>38</td>
<td>3.1</td>
<td>0.9</td>
<td>36</td>
<td>84.4% -0.70 [-1.13, -0.27]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>58</td>
<td>56</td>
<td>-0.70 [-1.09, -0.30]</td>
<td>-0.70 [-1.09, -0.30]</td>
</tr>
<tr>
<td>Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 0.96); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 3.43 (P = 0.0006)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2.3 6 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chitsazi et al., 2017</td>
<td>3.54</td>
<td>1.45</td>
<td>20</td>
<td>4.92</td>
<td>1.53</td>
<td>20</td>
<td>21.5% -1.38 [-2.30, -0.46]</td>
<td></td>
</tr>
<tr>
<td>Tinto et al., 2019</td>
<td>2.45</td>
<td>0.91</td>
<td>10</td>
<td>2.67</td>
<td>0.85</td>
<td>10</td>
<td>27.3% -0.22 [-0.99, 0.55]</td>
<td></td>
</tr>
<tr>
<td>El-Sharkawy et al., 2019</td>
<td>2.3</td>
<td>0.9</td>
<td>38</td>
<td>3</td>
<td>0.8</td>
<td>36</td>
<td>51.3% -0.70 [-1.08, -0.31]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>68</td>
<td>66</td>
<td>-0.72 [-1.22, -0.21]</td>
<td>-0.72 [-1.22, -0.21]</td>
</tr>
<tr>
<td>Heterogeneity: Tau² = 0.09; Chi² = 3.57, df = 2 (P = 0.17); I² = 44%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup differences: Chi² = 9.19, df = 2 (P = 0.01); I² = 78.2%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 4

The subgroup analysis presenting the WMDs of post-therapy on probing depth by comparing melatonin + NSPT vs. NSPT only groups at 2-, 3- and 6-month follow-ups.
Figure 5

The subgroup analysis presenting the difference of post-therapy on clinical attachment loss by comparing melatonin + NSPT vs. NSPT only groups at 2-, 3- and 6-month follow-ups.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Experimental</th>
<th>Control</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Melatonin+NSPT groups</td>
<td>Only NSPT groups</td>
<td>IV, Fixed, 95% CI</td>
<td>IV, Fixed, 95% CI</td>
</tr>
<tr>
<td>1.7.1 2 months</td>
<td>1.59 0.59 22  2.77 0.68 22  100.0%  -1.18 [-1.56, -0.80]</td>
<td>22  100.0%  -1.18 [-1.56, -0.80]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bazyar et al., 2018</td>
<td>4.23 1.43 20  5.14 1.23 20  23.4%  -0.91 [-1.74, -0.08]</td>
<td>58  100.0%  -0.83 [-1.23, -0.43]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chitsazi et al., 2017</td>
<td>3.22 1.52 20  4.56 1.16 20  26.6%  -1.34 [-2.18, -0.50]</td>
<td>58  100.0%  -0.94 [-1.38, -0.51]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>El-Sharkawy et al., 2019</td>
<td>2.6 1 38  3.4 1.2 36  73.4%  -0.80 [-1.30, -0.30]</td>
<td>58  100.0%  -0.31 [-1.22, 0.59]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Test for subgroup differences: Chi² = 1.67, df = 2 (P = 0.43), I² = 0%

Figure 6

The subgroup analysis presenting the WMDs of post-therapy on probing depth by comparing melatonin + NSPT vs. NSPT only groups according health statuses.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TableS1.docx